Detalles de la búsqueda
1.
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Circulation
; 145(3): 184-193, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779658
2.
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.
J Card Fail
; 29(10): 1345-1354, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37558088
3.
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Diabetes Obes Metab
; 25(3): 832-843, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36478142
4.
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
Eur Heart J
; 42(13): 1203-1212, 2021 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33420498
5.
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Eur Heart J
; 42(6): 700-710, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33351892
6.
Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile.
PLoS Genet
; 13(5): e1006756, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28542165
7.
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
Circulation
; 144(15): 1265-1267, 2021 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397263
8.
Tailored selection of study individuals to be sequenced in order to improve the accuracy of genotype imputation.
Genet Epidemiol
; 39(2): 114-21, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25537753
9.
Atlas of the clinical genetics of human dilated cardiomyopathy.
Eur Heart J
; 36(18): 1123-35a, 2015 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25163546
10.
A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy.
Eur Heart J
; 35(16): 1069-77, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23853074
11.
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
Eur J Heart Fail
; 25(1): 117-127, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36325584
12.
Responsiveness of efficacy endpoints in clinical trials with over the counter analgesics for headache.
Cephalalgia
; 32(13): 953-62, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22763497
13.
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
JACC Heart Fail
; 10(9): 651-661, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35780032
14.
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Lancet Diabetes Endocrinol
; 10(1): 35-45, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861154
15.
Efficacy and Safety of Diclofenac + Capsaicin Gel in Patients with Acute Back/Neck Pain: A Multicenter Randomized Controlled Study.
Pain Ther
; 9(1): 279-296, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32221866
16.
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
Clin Colorectal Cancer
; 18(4): 269-279.e5, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31628043
17.
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
Eur J Heart Fail
; 21(7): 932-942, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31218819
18.
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.
Onco Targets Ther
; 11: 8575-8587, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30584317
19.
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
Onco Targets Ther
; 11: 8565-8573, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573970
20.
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Clin Lung Cancer
; 19(4): e465-e479, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29653820